

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	<b>10/535,280</b>
---------------------------	-------------------

<b>Filing Date</b>	<b>Herewith</b>
--------------------	-----------------

<b>First Named Inventor</b>	Simon Joel
-----------------------------	------------

Art Unit	To Be Determined
----------	------------------

Examiner Name	To Be Determined
---------------	------------------

Attorney Docket Number	KLBS0005-100
------------------------	--------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
TDCC/	AC	WO 02/046129	06-13-2002	Abbott Lab.		
↓	AD	WO 02/076941	10-03-2002	Circagen Phrm.		
	AE	WO 02/055688	07-18-2002	U.S. Gov.		
	AF	WO 02/15921	02-28-2002	U.S. Gov.		
	AG	WO 02/08273	01-31-2002	Millennium Phrm.		
	AH	WO 02/069947	09-12-2002	Methylgene		
	AI	WO 02/062773	08-15-2002	F. Hoffmann-LA		
	AJ	WO 02/060430	08-08-2002	Cornell Research		
↓	AK	WO 02/50285	06-27-2002	Novartis		
	AL	WO 02/50244	06-27-2002	ISIS Pharm.		

**Examiner  
Signature**

/Deborah Carr/

Date Considered

09/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete If Known**

Application Number	10/535,280
Filing Date	Herewith
First Named Inventor	Simon Joel
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	KLBS0005-100

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/DDC/	AM	WO 02/36783	05-10-2002	Bayer		
	AN	WO 02/30970	04-18-2002	Bayer		
	AO	WO 01/42437	06-14-2001	Axys Phrm.		
	AP	WO 02/07722	01-31-2002	Georg-Speyer-Haus		
	AQ	WO 01/67107	09-13-2001	Imperial College		
	AR	WO 01/38322	05-31-2001	Methylgene		
	AS	WO 01/70675	09-27-2001	Methylgene		
	AT	GB 2101600	01-19-1983	Montedison		

Examiner  
Signature

/Deborah Carr/

Date  
Considered

09/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

**Complete if Known**

Application Number

10/535,280

Filing Date

Herewith

First Named Inventor

Simon Joel

Art Unit

To Be Determined

Examiner Name

To Be Determined

Attorney Docket Number

KLBS0005-100

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/DDC/	AU	Marks et al., "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells," <i>Journal of the National Cancer Institute</i> (2000) 92(15):1210-1216.	
	AV	Marks et al., "Histone deacetylases and cancer: causes and therapies," <i>Nat Rev Cancer</i> (2001) 1(3):194-202.	
	AW	Ma et al., "The synthesis of diencarbamates as adept prodrug models," <i>Synthetic Communications</i> (1997) 24(14):2445-2454.	
	AX	Cass et al., "On the preparation and rearrangement of some vinylic sulphoxides," <i>Journal of the Chemical Society</i> (1991) No. 11, pp. 2683-2686.	
	AY	Gourdie et al., "DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard," <i>Journal of Medicinal Chemistry</i> (1990) 33(4):1177-1186.	
	AZ	Flemming et al., "gamma-Sulphenylation of $\alpha,\beta$ -unsaturated aldehydes, ketones, and esters: the use of O-silylated dienolates," <i>Tetrahedron Letters</i> (1979) No. 34, pp. 3205-3208.	
	BA	Cai et al., "CD exciton chirality method. New red-shifted chromophores for hydroxyl groups," <i>Journal of the American Chemical Society</i> (1993) 115(16):7192-7198.	
	BB	Barrett et al., "Total synthesis of (+)-milbemycin $\beta_3$ ," <i>Journal of Organic Chemistry</i> (1986) 51(25):4840-4856.	
	BC	Bunce et al., "Functionalised carbocycles by tandem dealkoxycarbonylation-Michael addition reactions," <i>Journal of Organic Chemistry</i> (1993) 58(25):7143-7148.	
	BD	Database Accession No. 1969:37237 Caplus Abstract.	
✓	BE	Kalgutkar et al., "Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators," <i>Journal of Medicinal Chemistry</i> (1998) 41(24):4800-4818.	

Examiner  
Signature

/Deborah Carr/

Date  
Considered

09/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number	10/535,280
Filing Date	Herewith
First Named Inventor	Simon Joel
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	KLBS0005-100

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/DDC/	BF	Cowart et al., "Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase," <i>Journal of Medicinal Chemistry</i> (1998) 41(14):2636-2642.	
/DDC/	BG	Dannhardt et al., "[2-Aryl-pyrrolo[2,1-b]benzothiazoles as a selective or dual inhibitors of cyclo-oxygenases and 5-lipoxygenases. 21. Non-steroidal anti-inflammatory agents]," <i>Die Pharmazie</i> (1997) 52(6):428-436. (German)	
/DDC/	BH	Yoshida et al., "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.," <i>Journal of Biological Chemistry</i> (1990) 265(28):17174-17179.	

Examiner  
Signature

/Deborah Carr/

Date  
Considered

09/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.